| 前收市價 | 0.1200 |
| 開市 | 無 |
| 買盤 | 0.0100 |
| 賣出價 | 0.1000 |
| 拍板 | 114.00 |
| 到期日 | 2024-05-24 |
| 今日波幅 | 0.1200 - 0.1200 |
| 合同範圍 | 無 |
| 成交量 | |
| 未平倉合約 | 2 |
ZacksMerck (MRK) Ends Keytruda Combo Melanoma Study Due to Futility
Merck (MRK) discontinues the Keytruda plus vibostolimab co-formulation arm of a phase III study due to a higher rate of patient discontinuation.
BenzingaMerck Halts Skin Cancer Drug Trial On High Discontinuation Rate - A Setback in High-Risk Melanoma Treatment
Monday, Merck & Co Inc (NYSE:MRK) announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the Phase 3 KeyVibe-010 trial. The trial evaluates the investigational coformulation of vibostolimab and Keytruda (pembrolizumab) compared to Keytruda alone as adjuvant treatment for patients with resected high-risk melanoma (Stage IIB-IV). Also Read: Merck Stock Gains On Its Blockbuster Cancer Drug Keytruda, Raises Annual Outlook. Data from a pre-planned analysis showed tha
ZacksInvestors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
